Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 19/20 | 0.49 |
| ▸ | CTSL | P07711 | 7/20 | 0.49 |
| ▸ | CTSS | P25774 | 7/20 | 0.49 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6475769 | 1.00 | CTSK (0.49) | CTSKCTSLCTSSTAS1R3TAS1R1 | |
| SCHEMBL6475486 | 0.93 | CTSK (0.52) | CTSKCTSLCTSS | |
| SCHEMBL6475476 | 0.93 | CTSK (0.52) | CTSKCTSLCTSS | |
| SCHEMBL6484711 | 0.89 | CTSK (0.49) | CTSKCTSLCTSS | |
| SCHEMBL6484718 | 0.89 | CTSK (0.49) | CTSKCTSLCTSS | |
| SCHEMBL6484583 | 0.87 | CTSK (0.41) | CTSKCTSLCTSS | |
| SCHEMBL6484594 | 0.87 | CTSK (0.41) | CTSKCTSLCTSS | |
| SCHEMBL6486243 | 0.87 | CTSK (0.40) | CTSKCTSLCTSS | |
| SCHEMBL6486233 | 0.87 | CTSK (0.40) | CTSKCTSLCTSS | |
| SCHEMBL6475375 | 0.86 | CTSK (0.54) | CTSKCTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050020588-A1 | Cysteine protease inhibitors | PEPTIMMUNE, INC. | 2005-01-27 | — | — | US | claimed |
| US-20030203900-A1 | Cysteine protease inhibitors | MEDIVIR UK LTD (GB) | 2003-10-30 | — | — | US | claimed |
| US-20050020588-A1 | Cysteine protease inhibitors | PEPTIMMUNE, INC. | 2005-01-27 | — | — | US | disclosed |
| US-20030203900-A1 | Cysteine protease inhibitors | MEDIVIR UK LTD (GB) | 2003-10-30 | — | — | US | disclosed |
| EP-1345931-A2 | CYSTEINE PROTEASE INHIBITORS | Medivir UK Ltd (GB) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002040462-A2 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LIMITED (GB) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020588-A1 | Cysteine protease inhibitors | CTSS, CTSE, CTSV | CTSK 4/4885CTSL 11/4885CTSS 1/4885 |
| US-20030203900-A1 | Cysteine protease inhibitors | CTSS, CTSE, CTSV | CTSK 4/4885CTSL 11/4885CTSS 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.